(4S)-isobutyl-(3S)-methylpyrrolidin-2-one | 474924-92-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (4S)-isobutyl-(3S)-methylpyrrolidin-2-one
• 英文别名: 4-iso-butyl-3-methyl-pyrrolidin-2-one；(3S,4S)-3-methyl-4-(2-methylpropyl)pyrrolidin-2-one
• CAS: 474924-92-0
• 化学式: C₉H₁₇NO
• 分子量: 155.24
• InChiKey: UIVRIEDZVPWSKO-JGVFFNPUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (4S)-isobutyl-(3S)-methylpyrrolidin-2-one 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 生成 (3S,4S)-3-methyl-4-(2-methylpropyl)pyrrolidine
  参考文献：
  名称：

  锂化N-Boc烯丙基胺和苄基胺与硝基烯烃的共轭加成中的不对称碳-碳键形成：取代哌啶、吡咯烷和嘧啶酮的对映选择性合成

  摘要：

  (-)-Sparteine 介导的 N-Boc-烯丙基胺和苄基胺的锂化提供了构型稳定的中间体，这些中间体通过与硝基烯烃的共轭加成以良好的收率和高非对映选择性提供高度对映体富集的烯氨基甲酸酯产物。这些加合物的直接转化为取代 3,4-取代哌啶、3,4-取代吡咯烷和 4,5-取代嘧啶酮提供了一般途径。中间体内酰胺的非对映选择性取代随后还原提供 3,4,5-取代的哌啶和 3,4-三取代的吡咯烷。与 3,4-取代哌啶和吡咯烷的氮相邻的锂化，然后进行非对映选择性取代，开辟了一条通往 2,4,5-和 2,4,5,6-取代哌啶以及 2,3,4-和 2 的路线， 3,4,5-取代的吡咯烷。烯氨基甲酸酯和 3,4-取代哌啶产物的对映异构体可以通过甲锡酰化/金属转移序列以及通过进一步操作 4-取代哌啶酮来获得。该方法用于合成天冬氨酸肽酶抑制剂中间体 3-羟基-4-苯基哌啶以及抗抑郁药 (+)-非莫西汀的两种对映异构体。

  DOI：

  10.1021/ja0271375
• 作为产物：
  描述：

  (S)-2-isobutylsuccinic acid 4-O-t-butyl ester 在 镍 正丁基锂 、 sodium azide 、 dimethyl sulfide borane 、 氢溴酸 、 氢气 、 对甲苯磺酸 、 二异丙胺 作用下， 以 四氢呋喃 、 甲醇 、 正己烷 、 二甲基亚砜 为溶剂， -78.0~60.0 ℃ 、330.95 kPa 条件下， 反应 46.33h， 生成 (4S)-isobutyl-(3S)-methylpyrrolidin-2-one
  参考文献：
  名称：

  Structure−Activity Relationships of Pregabalin and Analogues That Target the α₂-δ Protein

  摘要：

  Pregabalin exhibits robust activity in preclinical assays indicative of potential antiepileptic, anxiolytic, and antihyperalgesic clinical efficacy. It binds with high affinity to the alpha(2)-delta subunit of voltage-gated calcium channels and is a substrate of the system L neutral amino acid transporter. A series of pregabalin analogues were prepared and evaluated for their alpha(2)-delta binding affinity as demonstrated by their ability to inhibit binding of [H-3]gabapentin to pig brain membranes and for their potency to inhibit the uptake of [H-3]leucine into CHO cells, a measure of their ability to compete with the endogenous substrate at the system L transporter. Compounds were also assessed in vivo for their ability to promote anxiolytic, analgesic, and anticonvulsant actions. These studies suggest that distinct structure activity relationships exist for alpha(2)-delta binding and system L transport inhibition. However, both interactions appear to play an important role in the in vivo profile of these compounds.

  DOI：

  10.1021/jm049762l

文献信息

• Asymmetric Carbon−Carbon Bond Formations in Conjugate Additions of Lithiated <i>N</i>-Boc Allylic and Benzylic Amines to Nitroalkenes:  Enantioselective Synthesis of Substituted Piperidines, Pyrrolidines, and Pyrimidinones
  作者：Timothy A. Johnson、Doo Ok Jang、Brian W. Slafer、Michael D. Curtis、Peter Beak

  DOI：10.1021/ja0271375

  日期：2002.10.1

  provide 3,4,5-substituted piperidines and 3,4-trisubstituted pyrrolidines. Lithiation adjacent to nitrogen of 3,4-substituted piperidines and pyrrolidines followed by diastereoselective substitution opens a route to 2,4,5- and 2,4,5,6-substituted piperidines as well as 2,3,4- and 2,3,4,5-substituted pyrrolidines. The enantiomers of the enecarbamate and 3,4-substituted piperidine products may be accessed

  (-)-Sparteine 介导的 N-Boc-烯丙基胺和苄基胺的锂化提供了构型稳定的中间体，这些中间体通过与硝基烯烃的共轭加成以良好的收率和高非对映选择性提供高度对映体富集的烯氨基甲酸酯产物。这些加合物的直接转化为取代 3,4-取代哌啶、3,4-取代吡咯烷和 4,5-取代嘧啶酮提供了一般途径。中间体内酰胺的非对映选择性取代随后还原提供 3,4,5-取代的哌啶和 3,4-三取代的吡咯烷。与 3,4-取代哌啶和吡咯烷的氮相邻的锂化，然后进行非对映选择性取代，开辟了一条通往 2,4,5-和 2,4,5,6-取代哌啶以及 2,3,4-和 2 的路线， 3,4,5-取代的吡咯烷。烯氨基甲酸酯和 3,4-取代哌啶产物的对映异构体可以通过甲锡酰化/金属转移序列以及通过进一步操作 4-取代哌啶酮来获得。该方法用于合成天冬氨酸肽酶抑制剂中间体 3-羟基-4-苯基哌啶以及抗抑郁药 (+)-非莫西汀的两种对映异构体。
• Structure−Activity Relationships of Pregabalin and Analogues That Target the α₂-δ Protein
  作者：Thomas R. Belliotti、Thomas Capiris、I. Victor Ekhato、Jack J. Kinsora、Mark J. Field、Thomas G. Heffner、Leonard T. Meltzer、Jacob B. Schwarz、Charles P. Taylor、Andrew J. Thorpe、Mark G. Vartanian、Lawrence D. Wise、Ti Zhi-Su、Mark L. Weber、David J. Wustrow

  DOI：10.1021/jm049762l

  日期：2005.4.1

  Pregabalin exhibits robust activity in preclinical assays indicative of potential antiepileptic, anxiolytic, and antihyperalgesic clinical efficacy. It binds with high affinity to the alpha(2)-delta subunit of voltage-gated calcium channels and is a substrate of the system L neutral amino acid transporter. A series of pregabalin analogues were prepared and evaluated for their alpha(2)-delta binding affinity as demonstrated by their ability to inhibit binding of [H-3]gabapentin to pig brain membranes and for their potency to inhibit the uptake of [H-3]leucine into CHO cells, a measure of their ability to compete with the endogenous substrate at the system L transporter. Compounds were also assessed in vivo for their ability to promote anxiolytic, analgesic, and anticonvulsant actions. These studies suggest that distinct structure activity relationships exist for alpha(2)-delta binding and system L transport inhibition. However, both interactions appear to play an important role in the in vivo profile of these compounds.